MedPath

吉林天成制药有限公司

Ownership
-
Established
2011-05-20
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

10

NMPA:10

Drug Approvals

Cisatracurium Besilate Injection

Product Name
苯磺顺阿曲库铵注射液
Approval Number
国药准字H20254237
Approval Date
May 20, 2025
NMPA

Cisatracurium Besilate Injection

Product Name
苯磺顺阿曲库铵注射液
Approval Number
国药准字H20254236
Approval Date
May 20, 2025
NMPA

Torasemide Injection

Product Name
托拉塞米注射液
Approval Number
国药准字H20223274
Approval Date
Apr 29, 2022
NMPA

Compound Troxerutin and Poreine Cerebroside Injection

Product Name
复方曲肽注射液
Approval Number
国药准字H22026578
Approval Date
Aug 10, 2020
NMPA

Compound Troxerutin and Poreine Cerebroside Injection

Product Name
复方曲肽注射液
Approval Number
国药准字H22026577
Approval Date
Aug 10, 2020
NMPA

Compound Troxerutin and Poreine Cerebroside Injection

Product Name
复方曲肽注射液
Approval Number
国药准字H22026579
Approval Date
Aug 10, 2020
NMPA

Compound Porcine Cerebroside and Ganglioside Injection

Product Name
复方脑肽节苷脂注射液
Approval Number
国药准字H22026457
Approval Date
Aug 10, 2020
NMPA

Compound Porcine Cerebroside and Ganglioside Injection

Product Name
复方脑肽节苷脂注射液
Approval Number
国药准字H22026472
Approval Date
Aug 10, 2020
NMPA

Compound Porcine Cerebroside and Ganglioside Injection

Product Name
复方脑肽节苷脂注射液
Approval Number
国药准字H22026502
Approval Date
Aug 10, 2020
NMPA

Ligustrazine Phosphate Injection

Product Name
磷酸川芎嗪注射液
Approval Number
国药准字H22026488
Approval Date
Aug 10, 2020
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.